GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (NAS:RYTM) » Definitions » PEG Ratio

RYTM (Rhythm Pharmaceuticals) PEG Ratio : 0.00 (As of Mar. 03, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Rhythm Pharmaceuticals PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Rhythm Pharmaceuticals's PE Ratio without NRI is 0.00. Rhythm Pharmaceuticals's 5-Year EBITDA growth rate is 1.60%. Therefore, Rhythm Pharmaceuticals's PEG Ratio for today is 0.00.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Rhythm Pharmaceuticals's PEG Ratio or its related term are showing as below:



RYTM's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.62
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Rhythm Pharmaceuticals PEG Ratio Historical Data

The historical data trend for Rhythm Pharmaceuticals's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Pharmaceuticals PEG Ratio Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Rhythm Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rhythm Pharmaceuticals's PEG Ratio

For the Biotechnology subindustry, Rhythm Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Pharmaceuticals's PEG Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Rhythm Pharmaceuticals's PEG Ratio falls into.



Rhythm Pharmaceuticals PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Rhythm Pharmaceuticals's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/1.60
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Rhythm Pharmaceuticals  (NAS:RYTM) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Rhythm Pharmaceuticals PEG Ratio Related Terms

Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhythm Pharmaceuticals Business Description

Traded in Other Exchanges
Address
222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Executives
Jennifer Chien officer: EVP, Head of North America C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Joseph Shulman officer: Chief Technical Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Hunter C Smith officer: CFO and Treasurer C/O GENESEE & WYOMING INC., 20 WEST AVENUE, DARIEN CT 06820
Pamela J. Cramer officer: Chief Human Resources Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
David P Meeker director C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
Jennifer L Good director 15 GREAT RING ROAD, SANDY HOOK CT 06482
Lynn A. Tetrault director 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Christopher Paul German officer: Corporate Controller & CAO C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Yann Mazabraud officer: EVP, Head of International C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510
William T. Roberts officer: Chief Accounting Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Linda Shapiro Manning officer: Chief Medical Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Todd Foley director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Camille L Bedrosian director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Nithya Desikan officer: Chief Commercial Officer 82 BAY STATE ROAD, BELMONT MA 02478